EQT Life Science develops medications, devices, and methods to combat it.
Business Model:
Revenue: $42.9M
Employees: 11-50
EQT life science was acquired by
EQT.
The acquisition happend on 2021-11-10.
Details of the transaction were not public
Address: Johannes Vermeerplein 9
City: Amsterdam
State: noord-holland
Zip: 1071 DV
Country: NL
EQT life science develops innovative medicines, devices and tools to address the single most important thing that matters to all the preservation of health. The organization believes that such opportunities add value to all stakeholders.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|---|---|---|
1/2016 | Rainier Therapeutics | Series A | 13M |
4/2020 | Kiadis Pharma | Post-IPO Equity | 5.5M |
6/2011 | Mendor | Series B | 11.7M |
1/2023 | Amolyt Pharma | Series C | 0 |
1/2016 | ViCentra | Series B | 10.9M |
9/2014 | Affimed | Series E | 0 |
9/2016 | Immunic Therapeutics | Series A | 19.6M |
5/2020 | Arvelle Therapeutics | Series A | 0 |
11/2003 | Affectis Pharmaceuticals | Series A | - |
8/2007 | FlowCardia | Series C | 0 |
2/2010 | Promethera Biosciences | Series A | 7.3M |
11/2011 | Harvest Automation | Series B | 7.9M |
4/2000 | NewBiotics | Venture Round | 6.3M |
8/2007 | Isto Technologies | Series E | 0 |
10/2015 | Luxendo | Series A | 0 |
9/2021 | Amolyt Pharma | Series B | 0 |
5/2011 | Cobalt Technologies | Series D | 0 |
8/2018 | Artios Pharma | Series B | 0 |
9/2019 | Pharvaris | Series B | 66M |
7/2020 | Cybin | Series B | 0 |
1/2011 | Nexstim | Venture Round | 0 |
6/2009 | Pronota | Series B | 7.4M |
5/2019 | DNA Script | Series B | 38.5M |
1/2009 | BMEYE | Series A | - |
12/2007 | Vivendy Therapeutics | Series A | 15.4M |
5/2016 | Nouscom | Series A | 13.6M |
11/2017 | Xeltis | Series C | 53M |
3/2014 | Hybrigenics | Post-IPO Equity | 8.4M |
6/2022 | ImCheck Therapeutics | Series C | 0 |
4/2004 | NewBiotics | Series E | 4.6M |
2/2022 | Perfuze | Series A | 0 |
7/2021 | Artios Pharma | Series C | 0 |
5/2008 | Asoyia | Venture Round | 4M |
12/2006 | BMEYE | Series A | - |
11/2009 | Kreatech Diagnostics | Venture Round | 0 |
10/2007 | Hyperion Therapeutics | Debt Financing | 15M |
9/2007 | Nexstim | Venture Round | 10.9M |
4/2016 | Onward | Series A | 29.5M |
10/1999 | Devgen | Series B | 24.7M |
1/2012 | Pronota | Series C | 4.8M |
1/2007 | Movetis | Series A | 63.8M |
2/2010 | arGEN-X | Series A | 4.5M |
2/2009 | ActoGeniX | Private Equity Round | 17.4M |
2/2007 | ActoGeniX | Venture Round | 26.1M |
7/2019 | AM Pharma | Series F | 130.1M |
1/2019 | INNOVO by Atlantic Therapeutics | Series B | 32.1M |
11/2012 | Kiadis Pharma | Venture Round | 0 |
7/2001 | NewBiotics | Series C | 0 |
9/2016 | Vivasure Medical | Series C | 18.3M |
9/2017 | Immunic Therapeutics | Series A | 11.9M |
2/2006 | EyeSense AG | Series A | 0 |
2/2023 | Xeltis | Series D | 0 |
8/2022 | eTheRNA immunotherapies | Series B | 0 |
6/2022 | Ariceum Therapeutics | Series A | 0 |
12/2021 | ViCentra | Series C | 0 |
3/2010 | Seahorse Bioscience | Series D | 5M |
10/2015 | Sequana Medical | Series C | 0 |
8/2021 | Visus Therapeutics | Equity | 20M |
6/2020 | OneProjects | Series A | 12.4M |
1/2010 | Harvest Automation | Series A | 4M |
4/2014 | Heart Metabolics | Series A | 20M |
1/2007 | 4-Antibody AG | Series A | 18.4M |
10/2012 | Cobalt Technologies | Venture Round | 5M |
3/2019 | SNIPR Biome | Series A | 50M |
12/2014 | Xeltis | Series B | 33.5M |
4/2005 | DNage | Series A | 1.9M |
1/2016 | Pharvaris | Series A | 16.3M |
4/2006 | Pronota | Series A | 7.8M |
1/2010 | Merus | Series B | 0 |
4/2012 | Cobalt Technologies | Venture Round | 2.9M |
1/2005 | OctoPlus | Series B | 23.9M |
5/2018 | Rainier Therapeutics | Series B | 20M |
2/2007 | Prosensa | Series A | 18M |
9/2010 | Harvest Automation | Series A | 1.3M |
10/2013 | Harvest Automation | Series C | 11.8M |
5/2003 | Santarus | Series D | 51.4M |
7/2017 | Simplify Medical | Series B | 21M |
2/2018 | Simplify Medical | Series B | 23M |
3/2007 | Okairos | Series A | 9.6M |
7/2020 | DNA Script | Series B | 50M |
8/2007 | BioProcessors | Series C | 10M |
7/2002 | Scion Pharmaceuticals | Series B | 0 |
8/2006 | Pronota | Series A | 10.6M |
5/2021 | Binx Health | Series E | 0 |
7/2019 | Amolyt Pharma | Series A | 0 |
8/2015 | Kuros Biosciences | Post-IPO Equity | 15.3M |
6/2011 | Sapiens Steering Brain Stimulation | Series A | 18.7M |
11/2009 | Vivoryon Therapeutics | Series B | 0 |
1/2012 | Vivoryon Therapeutics | Venture Round | 19.4M |
7/2003 | PamGene | Series B | 11.3M |
11/2014 | Curetis | Series B | 0 |
10/2021 | DNA Script | Series C | 0 |
12/2018 | XyloCor Therapeutics | Series A | 17M |
4/2007 | Affimed | Series B | 32M |
10/2012 | Affimed | Series D | 20.1M |
12/2000 | PamGene | Series A | 6.2M |
8/2016 | Rotation Medical | Series B | 12M |
7/2014 | Rotation Medical | Series B | 27.2M |
1/2021 | Neurent Medical | Series B | 0 |
7/2009 | Pasteuria Bioscience | Series B | 0 |
12/2009 | Curetis | Series A | 27.9M |
2/2019 | Arvelle Therapeutics | Series A | 0 |
6/2007 | Kiadis Pharma | Venture Round | 0 |
3/2021 | XyloCor Therapeutics | Series A | 0 |
10/2021 | OneProjects | Series A | 8M |
5/2023 | VarmX | Series B | 0 |
6/2015 | Neuravi | Series B | 21.5M |
10/2007 | Syntaxin | Series B | 32M |
1/2012 | Prosensa | Venture Round | 0 |
2/2018 | Merus | Post-IPO Equity | 55.8M |
9/2019 | Nkarta Therapeutics | Series B | 114M |
7/2021 | Xilis | Series A | 0 |
12/2021 | AviadoBio | Series A | 0 |
7/2020 | ViCentra | Venture Round | 0 |
9/2012 | IlluminOss Medical | Series C | 0 |
3/2015 | Cardiac Dimensions | Equity | 15.2M |
1/2017 | Binx Health | Series D | 0 |
3/2023 | QurAlis | Series B | 0 |
12/2015 | Xeltis | Series B | 3.3M |
10/2008 | Cobalt Technologies | Series C | 0 |
4/2015 | Merus | Series C | 79.1M |
11/2009 | Trinity Biosystems | Debt Financing | 7.5M |
7/2011 | Binx Health | Series B | 27.1M |
10/2013 | Merus | Series B | 42.2M |
8/2021 | T-knife | Series B | 110M |
9/2018 | Endotronix | Series D | 0 |
9/2020 | Cardiac Dimensions | Series C | 17.5M |
5/2012 | Celladon | Venture Round | 10M |
10/2021 | Egle Therapeutics | Series A | 0 |
3/2016 | eTheRNA immunotherapies | Series A | 26.6M |
5/2017 | ImCheck Therapeutics | Series A | 21.9M |
5/2017 | Cardior Pharmaceuticals | Series A | 16.3M |
5/2003 | BioXell | Series B | 19.9M |
7/2020 | Vico Therapeutics | Series A | 31M |
3/2004 | 4-Antibody AG | Seed Round | 2.1M |
7/2014 | Mint Solutions | Series A | 6M |
11/2017 | Orphazyme | Post-IPO Equity | 0 |
8/2016 | Mint Solutions | Series B | 5.6M |
4/2020 | FoRx Therapeutics | Seed Round | 10.8M |
4/2021 | Onward | Venture Round | 0 |
12/2019 | ImCheck Therapeutics | Series B | 53.2M |
1/2010 | Kreatech Diagnostics | Series B | 0 |
4/2014 | Binx Health | Series B | 0 |
3/2017 | Rainier Therapeutics | Series B | 30M |
7/2020 | VarmX | Series B | 36.3M |
11/2016 | OxThera | Series D | 34.1M |
1/2010 | Cellerix | Series C | 37.7M |
11/2009 | Cellerix | Series B | 40.5M |
9/2007 | Cellerix | Series B | 37.2M |
4/2023 | Evommune | Series B | 50M |
11/2021 | HotSpot Therapeutics | Series C | 0 |
8/2021 | Cardior Pharmaceuticals | Series B | 0 |
4/2023 | Evommune | Series B | 0 |
3/2023 | QurAlis | Series B | 0 |
2/2023 | Xeltis | Series D | 0 |
1/2023 | Amolyt Pharma | Series C | 0 |
8/2022 | eTheRNA immunotherapies | Series B | 0 |
6/2022 | ImCheck Therapeutics | Series C | 0 |
6/2022 | Ariceum Therapeutics | Series A | 0 |
2/2022 | Perfuze | Series A | 0 |
12/2021 | ViCentra | Series C | 0 |
12/2021 | AviadoBio | Series A | 0 |
Name | Price |
---|
Name | Size | Announced Date |
---|